BioPorto A/S (FRA:2P4)

Revenue by Segment

Financials in millions DKK. Fiscal year is January - December.

Fiscal Year	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020	FY 2019	FY 2018	FY 2017	FY 2016	FY 2015
Period Ending	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020	Dec 31, 2019	Dec 31, 2018	Dec 31, 2017	Dec 31, 2016	Dec 31, 2015
NGAL Tests	23.05M	18.56M	14.86M	12.35M	13.43M
NGAL Tests Growth	24.23%	24.91%	20.29%	-8.03%	15.34%
Antibodies	10.78M	10.68M	12.03M	9.29M	6.79M
Antibodies Growth	0.95%	-11.24%	29.51%	36.81%	-27.89%
ELISA Kits	2.27M	1.67M	1.84M	2.55M	2.54M
ELISA Kits Growth	35.54%	-8.82%	-27.94%	0.28%	-46.53%
Royalty and Other Revenue	137.00K	45.00K	243.00K	64.00K	19.00K
Royalty and Other Revenue Growth	204.44%	-81.48%	279.69%	236.84%	-86.62%
Other Products and Licenses	-	-	-	-	423.00K
Other Products and Licenses Growth	-	-	-	-	-36.58%
Total	36.24M	30.96M	28.97M	24.25M	23.20M
Total Growth	17.07%	6.87%	19.44%	4.53%	-12.84%

Revenue by Geography

Financials in millions DKK. Fiscal year is January - December.

Fiscal Year	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020	FY 2019	FY 2018	FY 2017	FY 2016	FY 2015
Period Ending	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020	Dec 31, 2019	Dec 31, 2018	Dec 31, 2017	Dec 31, 2016	Dec 31, 2015
North America	20.63M	17.48M	14.95M	13.45M	10.37M
North America Growth	18.05%	16.89%	11.17%	29.66%	-19.81%
Europe	10.24M	9.71M	10.09M	7.71M	10.02M
Europe Growth	5.48%	-3.82%	30.90%	-23.04%	0.60%
Asia	5.37M	3.77M	3.92M	3.07M	2.81M
Asia Growth	42.34%	-3.70%	27.86%	9.23%	-11.82%
Other	-	-	7.00K	30.00K	8.00K
Other Growth	-	-	-76.67%	275.00%	-98.54%
Total	36.24M	30.96M	28.97M	24.25M	23.20M
Total Growth	17.07%	6.87%	19.44%	4.53%	-12.84%

Source: S&P Global Market Intelligence.